Overall impact
A (82)

Commentary

Haleon is a leader for overall positive impact. With an 'A' rating of 81.7 for overall impact (95th percentile compared to all companies), Haleon ranks 4th out of 30 industry peers, behind Sanofi, Assembly Biosciences and Astrazeneca, and ahead of Adynxx, Alimera Sciences, Kazia Therapeutics and 23 others. On top material causes for Haleon's industry (Pharmaceuticals & Biotech), Haleon performs well in Decent, Safe Work Opportunities (95.6 score), Child and Maternal Health (94.7), Racial Justice and Civil Rights (81.0) and 6 other causes where it received an 'A' score and performs poorly in Technology Innovation (20.7 score).
Screens
Alcohol - responsible marketing
Child safety
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Land use and biodiversity
Misleading communication
Norges Bank exclusion list
OECD Guidelines
Opioid controversies
Oppressive governments
Pharma controversies
Privacy breaches
Tobacco - GICS
UK sanctions list
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Impact
Cause HLN
Peer rank
Overall impact

Log in to view this information

Screens
Alcohol - responsible marketing
Child safety
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Land use and biodiversity
Misleading communication
Norges Bank exclusion list
OECD Guidelines
Opioid controversies
Oppressive governments
Pharma controversies
Privacy breaches
Tobacco - GICS
UK sanctions list
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Impact trend

Change in rating for overall impact

Log in to view this information

HLN Price
$9.65
Last available end-of-day price. Full disclosure
Revenue
$13.96 billion
Market cap
$37.85 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
2021
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
HLN
Description
No description available yet. Find out more about Haleon at https://www.haleon.com
Material causes
Ethos considers the following causes material for Haleon, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.